1. NIR light-controlled mitochondria-targeted delivery of carbon monoxide combined with histone deacetylase inhibition for synergistic anticancer therapy
    Qi Tang et al, 2022, Journal of Inorganic Biochemistry CrossRef
  2. Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel
    Qi Nie et al, 2023, Molecular Medicine Reports CrossRef
  3. Interactions of Histone Deacetylase 6 with DNA Damage Repair Factors Strengthen its Utility as a Combination Drug Target in High-Grade Serous Ovarian Cancer
    Jolene M. Duda et al, 2023, ACS Pharmacology & Translational Science CrossRef
  4. Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
    Husvinee Sundaramurthi et al, 2022, International Journal of Molecular Sciences CrossRef
  5. Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
    Hanieh Meteran et al, 2024, Journal of Clinical Medicine CrossRef
  6. Differential histone deacetylase inhibitor‐induced perturbations of the global proteome landscape in the setting of high‐grade serous ovarian cancer
    Jolene M. Duda et al, 2023, PROTEOMICS CrossRef
  7. HDAC6 promotes aggressive development of liver cancer by improving egfr mRNA stability
    Hong-Ying Dai et al, 2023, Neoplasia CrossRef
  8. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells
    Ji Yoon Kim et al, 2022, International Journal of Molecular Sciences CrossRef
  9. Structural characterization of fungus-specific histone deacetylase Hos3 provides insights into developing selective inhibitors with antifungal activity
    Ningning Pang et al, 2022, Journal of Biological Chemistry CrossRef
  10. Nanoscale drug delivery systems for cancer therapy using paclitaxel— A review of challenges and latest progressions
    Ghulam Mustafa et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
  11. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy
    Seong-Jun Park et al, 2021, Archives of Pharmacal Research CrossRef
  12. Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
    Fengyi Guo et al, 2022, Frontiers in Oncology CrossRef
  13. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms
    Yuanpei Wang et al, 2024, Cancer Chemotherapy and Pharmacology CrossRef
  14. Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy
    Muhammad Shahab et al, 2023, Scientific Reports CrossRef
  15. Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
    Milan Beljkas et al, 2023, Pharmaceutics CrossRef
  16. HDAC6: A unique HDAC family member as a cancer target
    Sumeet Kaur et al, 2022, Cellular Oncology CrossRef